Cushing’s disease is a progressive pituitary disorder in which there is an excess of cortisol in the body. While the disease can be treated surgically, this option is not possible for all patients. This is one of the approved medications that assist in controlling cortisol levels in people with Cushing’s disease. Korlym (mifepristone), developed and marketed by Corcept … Continue reading Basics: Meds – Korlym
Cushing’s Syndrome Patient Advisory Board: Patient Qualifier Virtual Patient Panel for Cushing’s Syndrome Patients Patients that are accepted will be compensated for their participation. Q1: Are you a U.S. Citizen and at least 18-years or older? Q2: Have you been diagnosed with Cushing’s Disease (CD) or endogenous Cushing’s syndrome (CS)? Q3: Did your doctor find … Continue reading $$$ Attention Cushing’s Patients ~ Patient Advisory Board $$$
Top Doctors Receiving Payments From this Company Totals listed account for all payments from August 2013 to December 2016. DOCTOR PAYMENTS PEJMAN COHAN Endocrinology, Diabetes & Metabolism BEVERLY HILLS, CA $116K RICHARD AUCHUS Internal Medicine ANN ARBOR, MI $50,682 TODD FRIEZE Endocrinology, Diabetes & Metabolism BILOXI, MS $40,012 ALAN COHEN Endocrinology, Diabetes & Metabolism MEMPHIS, TN $38,156 AMIR … Continue reading 💊 Top Doctors Receiving Payments From Corcept, makers of Korlym
Corcept Therapeutics is recruiting participants for its Phase 3 clinical trial evaluating relacorilant as a potential treatment for Cushing’s syndrome-related side effects such as high blood pressure and impaired glucose tolerance. Also, findings from the study “A Randomized-Withdrawal, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Selective Glucocorticoid Receptor Antagonist, Relacorilant, in Patients with … Continue reading 😷 Clinical Trial: Endogenous Cushing’s Syndrome Patients Sought for Phase 3 Trial Testing Relacorilant
